Last reviewed · How we verify
Placebo-Matching Atogepant
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling to prevent migraine.
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling to prevent migraine. Used for Migraine prevention in adults.
At a glance
| Generic name | Placebo-Matching Atogepant |
|---|---|
| Sponsor | AbbVie |
| Drug class | CGRP receptor antagonist |
| Target | CGRP receptor (calcitonin gene-related peptide receptor) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Atogepant works by antagonizing the calcitonin gene-related peptide receptor, a key mediator in migraine pathophysiology. By blocking CGRP receptor signaling in the central and peripheral nervous system, it reduces the frequency and severity of migraine attacks. This oral small-molecule approach provides preventive migraine therapy.
Approved indications
- Migraine prevention in adults
Common side effects
- Constipation
- Nausea
- Upper respiratory tract infection
Key clinical trials
- A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine (PHASE3)
- Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. (PHASE3)
- Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (PHASE3)
- 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine (PHASE3)
- Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo-Matching Atogepant CI brief — competitive landscape report
- Placebo-Matching Atogepant updates RSS · CI watch RSS
- AbbVie portfolio CI